Home
»
Press Room
»
AI In Oncology Market Size To Reach $38.91Bn By 2033

AI In Oncology Market Size To Reach $38.91 Billion By 2033

December 2025 | Report Format: Electronic (PDF)

AI In Oncology Market Growth & Trends

The global AI in oncology market size is expected to reach USD 38.91 billion by 2033, registering a CAGR of 24.77% from 2026 to 2033, according to a new report by Grand View Research, Inc. The market is anticipated to witness significant growth owing to increasing prevalence of cancer among the global population, propelling the need to develop technologically advanced products to diagnose, treat, and analyze cancer. For instance, the International Agency for Research on Cancer (IARC) expects over 20.7 million new cases in 2023. Moreover, AI enables early detection, crucial for lowering mortality, especially through efficient screening programs.

Emerging markets are witnessing a rising prevalence of cancer due to various factors, including lifestyle changes & aging populations. The surge in cancer cases in these markets creates a demand for advanced technologies like AI in oncology to improve early detection, personalized treatment, and overall patient outcomes. For instance, in January 2024, India's first AI-Precision Oncology Centre (POC) was launched at Apollo Cancer Centre in Bengaluru. The POC will utilize the vast possibilities offered by AI to help oncologists, patients, and caregivers achieve the best possible results within a specified time frame.

AI is transforming the field of oncology by integrating vast datasets from multi-omics analyses with the latest developments in deep learning and high-performance computing techniques. AI applications are expanding to include new detection, screening, diagnosis, and classification approaches, cancer genomics characterization, tumor microenvironment analysis, prognostic and predictive biomarkers assessment, and strategies for follow-up and drug discovery. For instance, in October 2022, Model Medicines launched an oncology program focusing on identifying and developing therapeutics against two epigenetic and oncogenic targets, focusing on applications for solid and hematological malignancies.

The major players operating in the market are adopting strategies such as collaborations and partnerships with a major focus on development of newer products to aid in the early diagnosis of cancer, meet rising demand, and enhance research and development pipeline. For instance, in December 2022, AstraZeneca collaborated with Clinithink to launch an AI project for lung cancer. This project aims to detect lung cancer at an early stage to aid in the developing of effective treatment.

Furthermore, in November 2022, Google Health entered into a partnership with iCAD, Inc. for the improvement of breast cancer screening using the company’s artificial intelligence technology. Additionally, a number of public and private organizations are focusing on funding and investment for R&D in AI-based oncology screening products. For instance, in March 2023, Artera received funding of USD 90 million for the launch and distribution of the ArteraAI Prostate Test, the first developed test for predicting therapy in localized prostate cancer.

key Request a free sample copy or view report summary: AI In Oncology Market Report

AI In Oncology Market Report Highlights

Based on component type, the hardware segment dominated the market with a revenue share of over 39.43% in 2025. Medical device manufacturers use AI technologies to innovate products to help healthcare providers enhance patient care.
Based on cancer type, the breast cancer segment held the largest revenue share of 20.99% in 2025. The dominance of this segment is attributed to increasing prevalence of breast cancer among the population.
Based on application, the diagnostics segment dominated the market with the largest revenue share of over 37% in 2025. Cancer diagnostics is an essential starting point for designing relevant therapeutic strategies and clinical management, and its AI-based advancement makes it more efficient and effective.
Based on end use, the hospitals segment dominated the market with a revenue share of over 48% in 2025.
North America dominated the AI in oncology market with a revenue share of over 45.81% in 2025 due to presence of well-developed digital infrastructure, favorable regulatory & reimbursement policies, and rising government initiatives to boost the adoption of AI technology in the healthcare industry.